# Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC

> **NCT06536868** · PHASE2 · RECRUITING · sponsor: **Second Hospital of Shanxi Medical University** · enrollment: 40 (estimated)

## Conditions studied

- Extensive-stage Small-cell Lung Cancer

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Etoposide
- **DRUG:** Carboplatin or Cisplatin
- **RADIATION:** Thoracic radiotherapy

## Key facts

- **NCT ID:** NCT06536868
- **Lead sponsor:** Second Hospital of Shanxi Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06536868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06536868, "Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06536868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*